Search for a command to run...
Professor of Genetics, Harvard Medical School · Author, Lifespan
Aging is an information problem — the body loses the epigenetic instructions that tell cells how to function. Sinclair's protocol targets NAD⁺ restoration, sirtuin activation, and mTOR suppression to slow the loss of that information and, in animal models, partially reverse it.
7 of 10 molecules matched in index
| Molecule | Dose | Timing | Tier | Hallmarks | Cart |
|---|---|---|---|---|---|
NMN Sinclair uses NMN; NR is a structural alternative with similar mechanism | 1 g | Morning, with first meal | II | Nutrient-sensing dysreg.Stem cell exhaustion | |
Resveratrol Sinclair takes with fat to improve bioavailability | 1 g | Morning, with yoghurt or olive oil (fat required for absorption) | II | Nutrient-sensing dysreg.Epigenetic alterations | |
TMG (betaine) Methyl donor to offset NMN-driven SAM depletion | 1 g | Morning | II | Telomere attritionEpigenetic alterations | |
Metformin Prescription only. Sinclair pauses on heavy exercise days (may blunt adaptation) | 500–1000 mg | Evening with dinner | I | Nutrient-sensing dysreg.Cellular senescence | Rx only |
Statin (rosuvastatin) Prescription only. Cardiovascular risk management. | 10 mg | Evening | I | Microbiome alterations | Rx only |
Vitamin D3 | 4000–5000 IU | Morning with fat | I | Disabled autophagyMicrobiome alterations | |
Vitamin K2 (MK-7) Paired with D3 for calcium routing | 180 µg | Morning with fat | II | Microbiome alterations | |
Quercetin Senolytic — Sinclair cycles this | 500 mg | Morning | II | Altered intercellular comm. | |
Spermidine | 1 mg | Morning | II | Disabled autophagy | |
Alpha lipoic acid (ALA) | 600 mg | Morning | II | Mitochondrial dysfunction |
Tier I = multiple RCTs in humans · Tier II = human trials, early stage · Tier III = mechanism / animal studies only
Metformin and statins are prescription medications. Sinclair's protocol is a self-experiment, not a clinical recommendation. The TAME trial (Targeting Aging with Metformin) is ongoing and will provide higher-quality evidence. Resveratrol bioavailability in humans remains debated; the SIRT1 activation mechanism is contested.
See how David's stack compares to Attia, Sinclair, Patrick, Huberman, and Johnson side-by-side.
Open comparison tool →